Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has granted quick observe designation to the investigational remedy MNV-201 for the therapy of myelodysplastic...
The U.S. Meals and Drug Administration (FDA) granted approval to Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) on Sept. 19, 2025, for subcutaneous...
